Abstract 2509: CDDO-Im induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells

Department of Pharmacology, Dartmouth Medical School, Hanover, NH, USA.
Cancer Prevention Research (Impact Factor: 4.44). 03/2011; 4(3):425-34. DOI: 10.1158/1940-6207.CAPR-10-0153
Source: PubMed


Breast cancer-associated gene 1 (BRCA1) protein plays important roles in DNA damage and repair, homologous recombination, cell-cycle regulation, and apoptosis. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Imidazolide, CDDO-Im) is a promising anticancer and chemopreventive agent with potent antiproliferative and apoptotic activities against a wide variety of cancer types. However, the mechanisms responsible for the selective apoptotic effects of CDDO-Im in cancer cells remain elusive. In the present work, CDDO-Im induced G2/M arrest and apoptosis in BRCA1-mutated mammary tumor cell lines. Prior to the induction of apoptosis, CDDO-Im induced DNA damage and the phosphorylation of H2AX followed by activation of the DNA damage response. Moreover, CDDO-Im also induced the generation of reactive oxygen species (ROS), which is associated with the induction of DNA damage, in both mouse and human tumor cells containing a BRCA1 mutation. The inhibition of ROS generation by uric acid prevented the induction of DNA damage by CDDO-Im. Furthermore, treatment with CDDO-Im did not induce ROS in nonmalignant MCF-10A breast epithelial cells or in E18-14C-27 breast cancer cells with wild-type BRCA1 genes and was not cytotoxic to normal mouse 3T3 fibroblasts, highlighting a selective therapeutic potential of CDDO-Im for BRCA1-associated breast cancer cells. Altogether, our results show that CDDO-Im induces ROS and subsequent DNA damage, thereby facilitating the activation of the DNA damage checkpoint, G2/M arrest, and finally apoptosis in BRCA1-mutated cancer cells. The particular relevance of these findings to the chemoprevention of cancer is discussed. Cancer Prev Res; 4(3); 425-34. ©2011 AACR.

Download full-text


Available from: Karen T Liby, Jul 25, 2014
  • Source
    • "CDDO was shown to inhibit proliferation and induce peroxisome proliferator-activated receptor-c (PPAR-c) in human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer cells [29] [30]. CDDO-Im induced apoptosis in estrogen receptor negative and BRCA1 null breast cancer cells, by inducing reactive oxygen species (ROS), and subsequently DNA damage [31] [32]. In another study, CDDO-Im in combination with Gemini vitamin D analog, ABXL0124, potently inhibited HER2 or ErbB2 overexpressing breast cancer cells and repressed downstream signaling proteins, such as pErk1/2, pAKT, c- Myc, cyclin D1 and Bcl-2 [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oleanolic acid (OA, 3β-hydroxyolean-12-en-28-oic acid) is a ubiquitous pentacyclic multifunctional triterpenoid, widely found in several dietary and medicinal plants. Natural and synthetic OA derivatives can modulate multiple signaling pathways including nuclear factor-κB, AKT, signal transducer and activator of transcription 3, mammalian target of rapamycin, caspases, intercellular adhesion molecule 1, vascular endothelial growth factor, and poly (ADP-ribose) polymerase in a variety of tumor cells. Importantly, synthetic derivative of OA, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), and its C-28 methyl ester (CDDO-Me) and C28 imidazole (CDDO-Im) have demonstrated potent antiangiogenic and antitumor activities in rodent cancer models. These agents are presently under evaluation in phase I studies in cancer patients. This review summarizes the diverse molecular targets of OA and its derivatives and also provides clear evidence on their promising potential in preclinical and clinical situations.
    Full-text · Article · May 2014 · Cancer letters
  • Source
    • "Another Nrf2 activator, CDDO-Imidazolide, attenuated cigarette smoke-induced emphysema and cardiac dysfunction in mice.[31]. However, both sulforaphane and CDDO-Imidazolide are known to have many off-target effects and toxicity [32], [33]. We also showed that in a 12 days-smoke model using mice, Nrf2 was reduced as compare to a day exposure thus mimicking what is observed in COPD [12], [34]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-oxidant capacity is crucial defence against environmental or endogenous oxidative stress. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor that plays a key defensive role against oxidative and cytotoxic stress and cellular senescence. However, Nrf2 signalling is impaired in several aging-related diseases, such as chronic pulmonary obstructive disease (COPD), cancer, and neurodegenerative diseases. Thus, novel therapeutics that enhance Nrf2 signalling are an attractive approach to treat these diseases. Nrf2 was stabilized by SKI-II (2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole), which is a known sphingosine kinase inhibitor, in human bronchial epithelial cell line, BEAS2B, and in primary human bronchial epithelial cells, leading to enhancement of anti-oxidant proteins, such as HO-1, NQO1 and GCLM. The activation of Nrf2 was achieved by the generation of inactive dimerized form of Keap1, a negative regulator of Nrf2 expression, which was independent of sphingosine kinase inhibition. Using mice that were exposed to cigarette smoke, SKI-II induced Nrf2 expression together with HO-1 in their lungs. In addition, SKI-II reduced cigarette smoke mediated oxidative stress, macrophages and neutrophil infiltration and markers of inflammation in mice. SKI-II appears to be a novel activator of Nrf2 signalling via the inactivation of Keap1.
    Full-text · Article · Feb 2014 · PLoS ONE
  • Source
    • "As a potent anti-tumor agent, oleanolic acid (OA) suppressed many malignant phenotypes of glioma cells [10]–[14]. Intriguingly, OA and its derivatives has no cytotoxicity to normal human cells [15], [16]. These inhibitory effects of OA are involved with its suppression of some specific intracellular signaling pathways, such as STAT3, JNK, Akt and NF-kappaB signaling pathways [10], [12], [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitogen-activated protein kinases/Extracellular signal-regulated kinase (MAPK/ERK) pathway is essential for migration and invasion of malignant glioma. It is efficient to inhibit migration and invasion of glioma cells by targeting this pathway. Oleanolic acid (OA) has been well demonstrated to suppress survival, growth and angiogenesis of glioma cells. However, it is still unknown if OA affects the migration and invasion of glioma cells. We utilized U-87 MG glioma cell lines and primary glioma cells from patients to study the effect of OA on migration and invasion of glioma cells with multidisciplinary approaches. In this study, we found that OA significantly decreased the ability of glioma cells to migrate and invade. Epithelial-mesenchymal transition (EMT) of glioma cells was also suppressed by OA treatment. Furthermore, MAPK/ERK pathway was greatly inhibited in glioma cells under OA treatment. MAPK/ERK reactivation induced by a recombinant lentiviral vector, Lv-MEK, was able to rescue the inhibitory effect of OA on migration and invasion of glioma cells. Taken together, we provided evidences that OA was a MAPK/ERK pathway-targeting anti-tumor agent. Although the concentrations we used exceeded its physiological level, OA may be used to prevent migration and invasion of glioma cells by developing its derivatives with enhanced bioactivity.
    Preview · Article · Aug 2013 · PLoS ONE
Show more